Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | GHSR | Q92847 | 13/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980962 | 0.82 | HTR6 (0.64) | HTR6DRD3DRD2HTR2C | |
| SCHEMBL6971600 | 0.80 | GHSR (0.74) | HTR6GHSRDRD3CYP2D6DRD2 | |
| SCHEMBL6980473 | 0.80 | HTR6 (0.58) | HTR6 | |
| SCHEMBL6973981 | 0.75 | HTR6 (0.59) | HTR6DRD3CYP2D6DRD2HTR2C | |
| SCHEMBL7086874 | 0.74 | HTR6 (0.59) | HTR6GHSRDRD3HTR2C | |
| SCHEMBL7085849 | 0.73 | HTR6 (0.56) | HTR6GHSRDRD3HTR2C | |
| SCHEMBL6979282 | 0.73 | HTR6 (0.60) | HTR6DRD3CYP2D6CYP2C9DRD2 | |
| SCHEMBL6978521 | 0.72 | HTR6 (0.61) | HTR6DRD3CYP2D6PFKFB3DRD2 | |
| SCHEMBL6981615 | 0.72 | HTR6 (0.54) | HTR6DRD3CYP2D6DRD2HTR2C | |
| SCHEMBL6975641 | 0.72 | HTR6 (0.62) | HTR6DRD3CYP2D6CYP2C9DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | claimed |
| US-6599904-B2 | 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-29 | — | — | US | disclosed |